Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma...

Area of Science:

• Oncolytic virotherapy
• Cancer cell death pathways
• Adenovirus research

Background:

• Telomelysin is a telomerase-dependent, replication-selective oncolytic adenovirus.
• Understanding its antitumor mechanism in soft tissue sarcoma is crucial.

Purpose of the Study:

• To investigate the cell death pathways induced by telomelysin in soft tissue sarcoma.
• To elucidate the roles of apoptosis and autophagy in telomelysin's antitumor activity.

Main Methods:

• Treatment of soft tissue sarcoma cells with telomelysin alone and in combination with 3-methyladenine (autophagy inhibitor) or Z-Val-Ala-Asp-CH2F (apoptosis inhibitor).
• Assessment of cell viability, apoptosis, autophagy, and cellular ATP levels.

Main Results:

• Telomelysin alone induced simultaneous apoptosis and autophagy.
• Autophagy inhibition (3-methyladenine) reduced cell viability and increased apoptosis and ATP levels, indicating autophagy is protective.
• Apoptosis inhibition (Z-Val-Ala-Asp-CH2F) increased ATP depletion and shifted cell death to necrosis, without affecting viability.

Conclusions:

• Telomelysin-mediated autophagy acts as a survival mechanism, not a death-promoting process, in soft tissue sarcoma.
• Targeting autophagy or apoptosis can modulate telomelysin's efficacy and cell death mode.
• These findings provide insights into optimizing oncolytic adenovirus therapy.